cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Novo's disappoint analysts, sending stock tumbling - MM+M Novo Nordisk defends disappointing next-gen

Do I have to go on a diet

Metformin is a common medication for managing type 2 diabetes that may be prescribed off-label when clinically appropriate to aid weight loss by reducing appetite and enhancing insulin sensitivity, helping to lower blood sugar levels and prevent complications

The gradual dose escalation recommended by the FDA balances efficacy with tolerability, but it means that full appetite suppression may not occur until higher doses are reached

Studies show that semaglutide increases feelings of fullness, so people eat less naturally and can reduce calorie intake by up to 30% , but everyone is different

Conclusion Tirzepatide use in RCTs over 26 to 72 weeks did not increase overall or specific cancer risk